Merck KGaA

Industry

  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Research, Analytical Equipment & Supplies
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Acadiana Ventures
  • Allergopharma Joachim Ganzer KG
  • AmpTec GmbH
  • Asceneuron
  • Biochrom AG
  • BioControl Systems
  • Chord Therapeutics
  • EMD Performance Materials
  • EMD Pharmaceuticals
  • EMD Serono
  • Erbi Biosystems
  • FloDesign Sonics
  • Grzybowski Scientific Inventions (GSI)
  • Intermolecular
  • JRH Biosciences
  • Laboratoires Richelet
  • Merck Hoei
  • Millipore
  • MilliporeSigma
  • Ormet Circuts
  • Serono
  • Sigma-Aldrich
  • Versum Materials
See more in Biomedtracker

Latest on Merck KGaA

Scrip

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

Merck KGaA is pursuing a Phase III program for its novel toll-like receptor 7/8 inhibitor enpatoran in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), despite

Scrip

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Merck KGaA has warned that volatility caused by US President Donald Trump’s cuts to academic research and plans for tariffs could hit its business, although CEO Belén Garijo has expressed doubts about

In Vivo

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

In the top alliance by deal value, ABL Bio entered a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier shu

In Vivo

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

A major development is underway in the South London borough of Sutton, with the £1bn London Cancer Hub project poised to create significant opportunities for biotech companies focused on oncology rese